Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity

Bian, Jinlei, Ren, Jie, Li, Yongren, Wang, Jubo, Xu, Xi, Feng, Yifan, Tang, Hui, Wang, Yajing +1 more·2018·Bioorganic Chemistry
DOI 10.1016/j.bioorg.2018.08.028

Cited by (155)

Items 101–155 of 155

  1. Synthesis and Antiproliferative Activity of Novel Quercetin-1,2,3-Triazole Hybrids using the 1,3-Dipolar Cycloaddition (Click) Reaction
    Elisabete P. Carreiro, Carlos M. Gastalho, Sofia Ernesto, Ana Rodrigues Costa, Célia Miguel Antunes, Anthony Joseph Burke · 2022 · Synthesis
  2. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
    Wang, Yungang, Deng, Shouyan, Xu, Jie · 2020 · Cancer Biology and Medicine
  3. Discovery of small molecule degraders for modulating cell cycle
    Liguo Wang, Zhouli Yang, Guangchen Li, Yongbo Liu, Chao Ai, Yu Rao · 2023 · Frontiers of Medicine
  4. Targeting the cell-cycle machinery for cancer therapy
    Yunhua Peng, Jiejing Liu, Hiroyuki Inuzuka, Jing Liu, Wenyi Wei · 2025 · Trends in Cell Biology
  5. Harnessing the Power of Natural Products for Targeted Protein Degradation
    Bo Zhu, Zheng Wu, Yiwen Shou, Kaili Zhao, Qinpei Lu, Jiang‐Jiang Qin, Hongwei Guo · 2025 · Medicinal Research Reviews
  6. Natural products are an important source for proteasome regulating agents
    Pei An, Lijun Zhang, Wei Peng, Yuying Chen, Qiuping Liu, Xin Luan, Hong Zhang · 2021 · Phytomedicine
  7. Molecules Inducing Specific Cyclin-Dependent Kinase Degradation and their Possible Use in Cancer Therapy
    Mingming Zheng, Xiaoyu Zhang, Weijiao Chen, Fei Xia, Huanaoyu Yang, Kai Yuan, Peng Yang · 2024 · Future Medicinal Chemistry
  8. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives
    Makenzie Vorderbruggen, Carlos A. Velázquez‐Martínez, Amarnath Natarajan, Adam R. Karpf · 2024 · International Journal of Molecular Sciences
  9. Toosendanin: upgrade of an old agent in cancer treatment
    Shuwei LI, Qingyi XIONG, Yiwen SHEN, Jiayi Lin, Lijun Zhang, Ye Wu, Jinmei Jin, Xin Luan · 2024 · Chinese Journal of Natural Medicines
  10. Major Advances in Emerging Degrader Technologies
    Hang Luo, Li Wu, Yujian He, Chong Qin, Xinjing Tang · 2022 · Frontiers in Cell and Developmental Biology
  11. Beyond Inhibition: Recent Advances of Heterobifunctional Molecules Targeting CDK9
    Junzhe Yin, Na Zhang, Tian Wang, Xuan Zhang · 2025 · Journal of Medicinal Chemistry
  12. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules
    Muhammad Zafar Irshad Khan, Adila Nazli, Youlu Pan, Jian‐Zhong Chen · 2022 · Current Medicinal Chemistry
  13. Regulation of cell signaling pathways by Wogonin in different cancers: Mechanistic review
    Ghazala Yasmeen Butt, Ülkü Özbey, Durr-e-shahwar Malik, Rükset Attar, Lara Youssef, Ammad Ahmad Farooqı · 2021 · Cellular and Molecular Biology
  14. Click Chemistry toward the Synthesis of Anticancer Agents
    Ashutosh Pal, Bimal Krishna Banik · 2022 · Heterocycles
  15. Selective CDK9 Degradation Using a Proteolysis-Targeting Chimera (PROTAC) Strategy
    Jayapal Reddy Mallareddy, Sarbjit Singh, Lidia Boghean, Amarnath Natarajan · 2021 · Future Medicinal Chemistry
  16. Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy
    Jie Yang, Qiao-Li Wang, Guo‐Kai Feng, Mu‐Sheng Zeng · 2020 · Advanced Therapeutics
  17. Advantages of PROTACs in achieving selective degradation of homologous protein families
    Luxi Yang, Xinfei Mao, Jingyi Zhang, Jing Shu, Wenhai Huang, Xiaowu Dong, Yinqiao Chen, Mingfei Wu · 2026 · Beilstein Journal of Organic Chemistry
  18. PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
    Anthony Feral, Guillaume Laconde, Muriel Amblard, Nicolas Masurier · 2020 · Advanced Therapeutics
  19. Diversified applications and research progress of plant-derived natural products in PROTAC technology
    Mingyu Ma, Jie Cheng, Jie Wang, Peiyue Cao, Wei Yan, Qian Jiang, Mengjia Yu, Yi Bi · 2025 · Bioorganic Chemistry
  20. Recent advance in macrocyclic CDK inhibitors
    Jiamin Zheng, Zhisen Zhang, Jinxin Liu, Ryan Shi, Feng Ren, Alex A. Zhavoronkov, Xiao Ding · 2025 · Future Medicinal Chemistry
  21. Azole–Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review
    Mihaela Lipovanu, Anca Miron, Nina Filip, Cristina Elena Horhogea, Ana Clara Aprotosoaie · 2026 · Pharmaceuticals
  22. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer
    Pradeep Pilania, Sisir Nandi, Dinesh Kumar Meena, Brij Kishore Sharma · 2024 · Current Signal Transduction Therapy
  23. Mechanisms of Action and Indications of Cyclin‐Dependent Kinase Inhibitors with Benzoheterocycle Scaffolds
    Gaojie Chang, Hailian Chen, Jiadai Zhai, Xuewei Jia, Yanzhi Wang, Liyan Zhang, Yuting Cui, Bingxia Sun, Jingquan Bi, Feng Sang · 2025 · ChemistrySelect
  24. PROTACs of cyclin-dependent kinases
    Denisa Veselá, Eva Řezníčková, Václav Mik, Radek Jorda · 2024 · Annual reports in medicinal chemistry
  25. Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
    Kexin Zhao, Jun Zhang, Zhe Yang, Rong Wang, Yuhuan Shi, Yanan Ji, Shengjun Zhang, Minli Liu · 2025 · Breast Cancer Targets and Therapy
  26. Harnessing the power of traditional Chinese medicine for targeted protein degradation
    Zheng Wu, Bo Zhu, Yiwen Shou, Hongwei Guo · 2025 · Elsevier eBooks
  27. Structural biology and computer-aided drug design
    Prabhakar Singh, Saqib Hassan, Mohammad Murtaza Mehdi, V. Ramesh Kumar, Kunal Biswas · 2025 · Elsevier eBooks
  28. Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
    Xing Tian, Xiaojie Dai, Ye Zhong, Maosheng Cheng, Yang Liu · 2025 · Pharmaceutical Fronts
  29. Opportunities and challenges in targeted protein degradation for antiviral drug discovery
    Man Zhu, Maoze Yang, Hai‐Bing Zhou · 2026 · Elsevier eBooks
  30. Discovery of selective CDK9 degraders with anti-AML activity using PROTAC technology
    Qing Li, Fuyuan Zhou, Ding Luo, Yan Yang, Tingting Hou, Junyang Chen, Jingsong Yu, Shilong Wu, Mingran Xu, Cheng Zou et al. · 2026 · Bioorganic Chemistry
  31. Linker attachment points: “finishing touch” in PROTAC design
    qiaojuan jiang, Hua-Sheng Shi, Chuan-Sheng Zhao, Zi-Yi Wang, Mei-Meng Yu, Xin-Yue Zhang, Cong-Jun Liu · 2026 · RSC Medicinal Chemistry
  32. BindingDB Entry 50020161: Advances of bioorthogonal coupling reactions in drug development.
    BindingDB · 2024 · UC San Diego
  33. BindingDB Entry 50022375: Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.
    BindingDB · 2025 · UC San Diego
  34. BindingDB Entry 50018749: PROTAC: A promising technology for cancer treatment.
    BindingDB · 2024 · UC San Diego
  35. BindingDB Entry 50019525: PROTACS: A technology with a gold rush-like atmosphere.
    BindingDB · 2024 · UC San Diego
  36. BindingDB Entry 50007767: Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    BindingDB · 2021 · UC San Diego
  37. BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
    BindingDB · 2024 · UC San Diego
  38. BindingDB Entry 50021665: The application of PROTAC in HDAC.
    BindingDB · 2025 · UC San Diego
  39. BindingDB Entry 50006137: Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities.
    BindingDB · 2024 · UC San Diego
  40. BindingDB Entry 50019284: Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation.
    BindingDB · 2024 · UC San Diego
  41. BindingDB Entry 50018341: A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
    BindingDB · 2024 · UC San Diego
  42. BindingDB Entry 50023431: Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer.
    BindingDB · 2026 · UC San Diego
  43. BindingDB Entry 50013929: Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    BindingDB · 2022 · UC San Diego
  44. BindingDB Entry 50018045: Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives.
    BindingDB · 2023 · UC San Diego
  45. BindingDB Entry 50012045: Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
    BindingDB · 2022 · UC San Diego
  46. BindingDB Entry 50018115: CDK9 inhibitors in cancer research.
    BindingDB · 2024 · UC San Diego
  47. BindingDB Entry 50019493: Review of bioactivity and structure-activity relationship on baicalein (5,6,7-trihydroxyflavone) and wogonin (5,7-dihydroxy-8-methoxyflavone) derivatives: Structural modifications inspired from flavonoids in Scutellaria baicalensis.
    BindingDB · 2024 · UC San Diego
  48. BindingDB Entry 50022023: Application and challenges of nitrogen heterocycles in PROTAC linker.
    BindingDB · 2025 · UC San Diego
  49. BindingDB Entry 50023478: PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications.
    BindingDB · 2026 · UC San Diego
  50. BindingDB Entry 50013823: Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
    BindingDB · 2022 · UC San Diego
  51. BindingDB Entry 50007847: Development of selective small molecule MDM2 degraders based on nutlin.
    BindingDB · 2021 · UC San Diego
  52. BindingDB Entry 50009433: Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
    BindingDB · 2021 · UC San Diego
  53. BindingDB Entry 50012065: Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
    BindingDB · 2022 · UC San Diego
  54. BindingDB Entry 50015993: Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.
    BindingDB · 2023 · UC San Diego
  55. BindingDB Entry 50008754: 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.
    BindingDB · 2021 · UC San Diego